Share-price performances in the pharmaceutical industry have exploded over the past 2-3 years, with many seeing returns in excess of 100%. But is this trend sustainable? Valuation wise, most of the pharmaceutical companies have yet to record any revenue, with only about 10% of the companies being cash flow positive. Nonetheless, the companies on our list today have seen its stock prices power more than 180% higher during the past year.
Mettrum Health Corp. (TSXV: MT) – $1.55
Pharmaceuticals
Mettrum Health Corp. (Mettrum), formerly Cinaport Acquisition Corp., is a Canada-based agri-pharmaceutical company, and through its wholly-owned subsidiary, Mettrum Ltd., is engaged in the research, development, production and distribution of cannabis products to the Canadian market. The Company also owns a 100% interest in Oilseed Works Inc. (OWI). OWI operates under the Hempola brand and is a Health Canada licensed producer and processor of cannabis-based products.
- Market Cap: $53,679,027
- EV/Revenue: N/A
- P/FCF: -3.22x
- Price Change (1 year): +998.7%
Theratechnologies Inc. (TH.TO) – $2.35
Pharmaceuticals
Theratechnologies Inc. is a Canada-based pharmaceutical company, which addresses unmet medical needs in metabolic disorders. The Company’s product EGRIFTA (tesamorelin for injection) has been approved by the United States Food and Drug Administration to help to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA (tesamorelin for injection) was also approved by Health Canada for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients.
- Market Cap: $138,940,329
- EV/Revenue: 10.62x
- P/FCF: -13.58x
- Price Change (1 year): +392.5%
Tribute Pharmaceuticals Canada Inc. (TSXV: TRX) – $1.84
Biotechnology & Medical Research
Tribute Pharmaceuticals Canada Inc. is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada with a particular interest in products for the treatment of neurology, pain, urology, dermatology and endocrinology/cardiology. Its current portfolio consists of 13 marketed products in Canada, including NeoVisc (Triple and Single Dose), Uracyst, Bezalip SR, Soriatane, Cambia, Fiorinal, Fiorinal C, Visken, Durela, Proferrin, Resultz, Viskazide and Collatamp G.
- Market Cap: $230,850,956
- EV/Revenue: 12.76x
- P/FCF: -6.30x
- Price Change (1 year): +238.3%
Trillium Therapeutics Inc. (TSX: TR) – $25.15
Pharmaceuticals
Trillium Therapeutics Inc. (Trillium), formerly Stem Cell Therapeutics Corp., is a Canada-based immuno-oncology company developing therapies for the treatment of cancer. The Company’s lead program, SIRPaFc, is an antibody-like protein that harnesses the innate immune system by blocking the activity of CD47, a molecule whose expression is increased on cancer cells to evade the host immune system. SIRPaFc is in pre-clinical development as a treatment for acute myeloid leukemia (AML).
- Market Cap: $183,190,290
- EV/Revenue: N/A
- P/FCF: -14.78x
- Price Change (1 year): +193.6%
Concordia Healthcare Corp. (TSX: CXR) – $101.16
Pharmaceuticals
Concordia Healthcare Corp. is a Canada-based diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.
- Market Cap: $3,417,367,882
- EV/Revenue: 22.53x
- P/FCF: 183.68x
- Price Change (1 year): +186.1%
